We provided a 'deep dive' on Geron last week to Biotech Forum subscribers. We passed on recommendation and advise Forum members to thread lightly given the stock's huge run up in previous months and because it violated the '10 Year Rule'. Unfortunately, for Geron shareholders, the stock did not prove to be the 'exception' to that rule.
